OnKure Therapeutics, Inc. — All Filings
345 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
144
3
3/A
4
4/A
424B3
424B4
424B5
425
8-A12B
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
EFFECT
POS AM
S-1
S-1/A
S-3
S-4
S-4/A
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| SCHEDULE 13G/A | — | 0001172661-25-002418 | May 19, 2025 | — |
| 4 | 4 | 0000950170-25-074459 | May 19, 2025 | May 15, 2025 |
| 4 | — | 0000929638-25-001950 | May 19, 2025 | May 15, 2025 |
| 4 | — | 0000929638-25-001870 | May 14, 2025 | May 12, 2025 |
| 424B3 | 424B3 | 0000950170-25-063972 | May 6, 2025 | — |
| 8-K | 8-K | 0000950170-25-063969 | May 6, 2025 | — |
| 10-Q | 10-Q | 0000950170-25-063970 | May 6, 2025 | Mar 31, 2025 |
| DEF 14A | DEF 14A | 0001140361-25-014183 | Apr 16, 2025 | May 27, 2025 |
| DEFA14A | DEFA14A | 0001140361-25-014186 | Apr 16, 2025 | — |
| ARS | ARS | 0000950170-25-054752 | Apr 16, 2025 | Dec 31, 2024 |
| 4 | — | 0001415889-25-010418 | Apr 8, 2025 | Apr 4, 2025 |
| 4 | — | 0001415889-25-010419 | Apr 8, 2025 | Apr 4, 2025 |
| 4 | 4 | 0000950170-25-049473 | Apr 2, 2025 | Mar 31, 2025 |
| 4 | — | 0001415889-25-009659 | Apr 2, 2025 | Mar 31, 2025 |
| 424B3 | 424B3 | 0001193125-25-061340 | Mar 24, 2025 | — |
| EFFECT | — | 9999999995-25-000731 | Mar 21, 2025 | — |
| POS AM | POS AM | 0001193125-25-058954 | Mar 20, 2025 | — |
| 424B3 | 424B3 | 0000950170-25-036341 | Mar 10, 2025 | — |
| S-8 | S-8 | 0000950170-25-036363 | Mar 10, 2025 | — |
| 8-K | 8-K | 0000950170-25-036306 | Mar 10, 2025 | — |
| 10-K | 10-K | 0000950170-25-036252 | Mar 10, 2025 | Dec 31, 2024 |
| SCHEDULE 13G/A | — | 0001172661-25-000885 | Feb 14, 2025 | — |
| SCHEDULE 13G/A | — | 0000902664-25-000772 | Feb 7, 2025 | — |
| SCHEDULE 13G/A | — | 0001415889-25-003306 | Feb 6, 2025 | — |
| SCHEDULE 13G | — | 0000932471-25-000246 | Jan 31, 2025 | — |
| 4 | — | 0001415889-25-002311 | Jan 29, 2025 | Jan 27, 2025 |
| 4 | — | 0001415889-25-002312 | Jan 29, 2025 | Jan 27, 2025 |
| 4 | — | 0001415889-25-002309 | Jan 29, 2025 | Jan 27, 2025 |
| 4 | — | 0001415889-25-002310 | Jan 29, 2025 | Jan 27, 2025 |
| SCHEDULE 13D/A | — | 0001104659-25-004963 | Jan 21, 2025 | — |
| 8-K | 8-K | 0000950170-24-134757 | Dec 10, 2024 | — |
| 424B3 | 424B3 | 0000950170-24-134758 | Dec 10, 2024 | — |
| S-8 | S-8 | 0000950170-24-134582 | Dec 9, 2024 | — |
| SC 13G/A | AMENDMENT NO. 1 | 0001214659-24-019110 | Nov 14, 2024 | — |
| SC 13G | ONKURE THERAPEUTICS, INC. | 0000902664-24-006543 | Nov 14, 2024 | — |
| 424B3 | 424B3 | 0000950170-24-123367 | Nov 7, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-123233 | Nov 7, 2024 | Sep 30, 2024 |
| 8-K | 8-K | 0000950170-24-123265 | Nov 7, 2024 | — |
| 424B3 | 424B3 | 0001193125-24-248666 | Oct 31, 2024 | — |
| EFFECT | — | 9999999995-24-003323 | Oct 30, 2024 | — |
| SC 13G/A | AMENDMENT NO. 1 | 0001214659-24-017999 | Oct 28, 2024 | — |
| CORRESP | — | 0001193125-24-245562 | Oct 28, 2024 | — |
| UPLOAD | — | 0000000000-24-011951 | Oct 25, 2024 | — |
| S-1 | S-1 | 0001193125-24-241926 | Oct 23, 2024 | — |
| SC 13G/A | — | 0001172661-24-004335 | Oct 23, 2024 | — |
| D | — | 0001748961-24-000002 | Oct 21, 2024 | — |
| SC 13G/A | — | 0000929638-24-003523 | Oct 16, 2024 | — |
| 3 | — | 0000929638-24-003520 | Oct 15, 2024 | Oct 4, 2024 |
| SC 13G | — | 0000929638-24-003493 | Oct 11, 2024 | — |
| SC 13G | SC 13G | 0001104659-24-108113 | Oct 11, 2024 | — |